Merck immunotherapy fails to improve survival in head and neck cancer – WHTC
|
Merck immunotherapy fails to improve survival in head and neck cancer
WHTC (Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a … |
